Tsujimura T, Ezaki K, Ono Y, Nakano H, Kawase K, Iwase K, Hatanaka T, Ohara K, Hobara R, Okamoto M
Dept. of Surgery, Fujita Health University School of Medicine.
Gan To Kagaku Ryoho. 1993 Mar;20(4):493-8.
Twenty-four patients with advanced or relapsed gastric or colorectal cancer were treated with a combination of 5-fluorouracil (5-FU), leucovorin (LV) and interferon-alpha (IFN-alpha). 5-FU was administered by rapid intravenous infusion at 350 mg/m2 for 5 consecutive days. Intravenous bolus administration of LV 20 mg/m2 was given before each 5-FU administration. This combination was repeated every 3 to 4 weeks. IFN-alpha (HLBI), 6MU, was administered subcutaneously daily. Of 13 patients with gastric cancer, there were 2 PR, 4 NC and 7 PD, and among 11 patients with colorectal cancer, there were 1 CR, 8 NC and 2 PD. All 16 previously treated patients had no clinical response. Responses were seen in patients with no prior chemotherapy and with good performance status. Most common toxicities observed were leucopenia, fever, stomatitis and diarrhea, which were all tolerable and reversible.
24例晚期或复发性胃癌或结直肠癌患者接受了5-氟尿嘧啶（5-FU）、亚叶酸钙（LV）和α-干扰素（IFN-α）联合治疗。5-FU以350mg/m²的剂量通过快速静脉输注连续给药5天。每次5-FU给药前静脉推注20mg/m²的LV。该联合方案每3至4周重复一次。IFN-α（HLBI），6MU，每日皮下注射。13例胃癌患者中，有2例部分缓解（PR），4例疾病稳定（NC），7例疾病进展（PD）；11例结直肠癌患者中，有1例完全缓解（CR），8例NC，2例PD。16例先前接受过治疗的患者均无临床反应。未接受过化疗且身体状况良好的患者出现了反应。观察到的最常见毒性为白细胞减少、发热、口腔炎和腹泻，这些毒性均可耐受且可逆。
